17 December 2015
EMA/847375/2015
EMEA/H/W/000673

Public statement

Lamivudine ViiV

Cessation of manufacture

GlaxoSmithKline Research & Development Ltd has informed the European Medicine Agency (EMA) of its decision to stop the manufacture of the HIV medicine Lamivudine ViiV for commercial reasons.

Lamivudine ViiV was evaluated by EMA under the Article 58 provision,[1] whereby EMA's Committee for Medicinal Products for Human Use (CHMP), in cooperation with the World Health organization (WHO), gives scientific opinions on medicines intended for use outside the EU.

The CHMP gave a positive opinion on Lamivudine ViiV in November 2005.

Following the decision of GlaxoSmithKline Research & Development Ltd, Lamivudine ViiV will no longer be available in the non-EU countries where it was authorised and the CHMP will not make further recommendations on its conditions of use.

Patients and healthcare professionals who have questions about alternative treatments should contact authorities in their country.

The European Public Assessment Report (EPAR) for Lamivudine ViiV will be updated to indicate that the medicine is no longer available.

[1] Regulation (EC) No 726/2004

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact